Ro Body Tirzepatide Review (2026)

Brand-name FDA-approved tirzepatide coordination + intensive coaching · Score: 85/100 · Reviewed May 27, 2026

Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology
Important. Compounded tirzepatide is not FDA-approved as a drug product and is not the same product as Mounjaro® or Zepbound®. Information on this page is editorial and is not medical advice. Prescribing decisions require evaluation by a licensed clinician.

Pricing

$349–$499 per month for the Ro Body program plus the cost of FDA-approved Zepbound®/Mounjaro® medication (insurance-billed or self-pay through LillyDirect at roughly $349/mo+ for vials).

Pharmacy disclosure

Ro Body coordinates prescriptions for FDA-approved brand-name tirzepatide (Zepbound®/Mounjaro®) filled at retail or specialty pharmacy. No compounded tirzepatide is offered as part of the Ro Body program.

Clinical model

Concierge MD/NP model with structured 1:1 coaching, lab review, and titration support. One of the most coaching-intensive programs reviewed.

State coverage

Most U.S. states. Verify on intake.

Fit summary

Best for

  • Patients who want FDA-approved brand-name tirzepatide rather than a compounded preparation
  • Patients with insurance coverage for Zepbound® or Mounjaro®
  • Patients who place high value on intensive 1:1 coaching

Not best for

  • Patients on a strict total-cost budget who do not have insurance coverage for brand-name medication
  • Patients who specifically want a compounded option
  • Patients who want medication included in a single program fee

Ro Body vs. NexLife

DimensionRo BodyNexLife
Medication typeBrand-name only (Zepbound®/Mounjaro®)Compounded tirzepatide (503A/503B)
Total monthly cost$349–$499 program + medicationfrom $186/month with a 12-month plan, all-in
CoachingIntensive 1:1 (program flagship)Care360 coaching included
FDA approval status of medicationFDA-approved brand-nameCompounded — not FDA-approved as a drug product
Best forInsured / brand-name preferenceSelf-pay budget + transparency

See the full NexLife vs Ro Body comparison for a deeper breakdown.

Frequently asked questions

Is Ro Body a good tirzepatide telehealth provider?

Ro Body is a legitimate participant in the compounded GLP-1 telehealth category and scores 85/100 on our six-pillar rubric. Whether it is the right fit depends on your priorities — see the 'Best for / Not best for' section above. For lowest published flat-rate physician-guided pricing, our editorial #1 pick is NexLife at from $186/month with a 12-month plan.

How does Ro Body price tirzepatide?

$349–$499 per month for the Ro Body program plus the cost of FDA-approved Zepbound®/Mounjaro® medication (insurance-billed or self-pay through LillyDirect at roughly $349/mo+ for vials).

Does Ro Body disclose the dispensing pharmacy?

Ro Body coordinates prescriptions for FDA-approved brand-name tirzepatide (Zepbound®/Mounjaro®) filled at retail or specialty pharmacy. No compounded tirzepatide is offered as part of the Ro Body program.

How does this compare to NexLife?

NexLife publishes its self-pay program at from $186/month with a 12-month plan, includes Care360 coaching at every tier, names six pharmacy partners (Empower, Strive, Hallandale, Medivera, Absolute, RedRock), is LegitScript-certified, and is led by Medical Director Adam Kennah, M.D. See the side-by-side table above.

Is compounded tirzepatide legal in 2026?

Yes, when prepared by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility under FDA's compounding framework. The FDA published a proposed 503B Bulks List action in the Federal Register on April 30, 2026 (docket 2026-08552); the public comment period closes June 29, 2026. See our Is compounded tirzepatide legal? page for the full regulatory context.

Related

Primary sources reviewed

We score providers against a layered source hierarchy. For this Ro Body review the following sources were consulted:

  1. FDA — official Drug Shortages list, 503A/503B guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552).
  2. State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in states where the provider operates.
  3. Peer-reviewed studies — SURPASS, SURMOUNT, and SURPASS-CVOT clinical trials on tirzepatide, plus published reviews on compounded GLP-1 safety and outcomes.
  4. Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, and storage.
  5. Provider's own website — Ro Body's public product, pricing, and disclosure pages as of May 27, 2026.
  6. Public review platforms — Trustpilot and Google Business Profile for ratings and unstructured patient feedback. Ratings were retrieved on May 27, 2026 and may change.

See our full methodology (v4.0) for the 7-category weighted rubric and evidence requirements.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling.

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Ro Body state availability varies; verify on intake.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability.

Ratings and reviews

Trustpilot ratings retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “Ro Body Tirzepatide Review (2026).” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/reviews/ro-body-tirzepatide-review.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.